{{ 'fb_in_app_browser_popup.desc' | translate }} {{ 'fb_in_app_browser_popup.copy_link' | translate }}

{{ 'in_app_browser_popup.desc' | translate }}

MENU CART {{currentCart.getItemCount()}}
The maximum number of items is 100, please adjust the quantity and purchase again

FDA approves use of drug to reduce risk of cardiovascular events in certain adult

patient groups (December 13, 2019)

日期: 2020-05-04


The U.S. Food and Drug Administration today approved the use of Vascepa (icosapent ethyl) as an adjunctive (seco

ndary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of f

at in the blood) of 150 milligrams per deciliter or higher. Vascepa is the first FDA approved drug to reduce cardiovas

cular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.